Pharmacy Website
Clinic Website

Intelligence » Hepatitis C » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients

Monday, December 03, 2018 -- by Monika Rau, Johannes Schmitt, Thomas Berg, Andreas E. Kremer, Bruno Stieger, Katharina Spanaus, Bertram Bengsch, Marta R. Romero, Jose J. Marin, Verena Keitel, Hartwig Klinker, Hans-Peter Tony, Beat Müllhaupt, Andreas Geier Background & aims Serum interferon-gamma-inducible protein-10 (IP-10) is elevated in cholestatic liver diseases and predicts response to antiviral therapy in patients with chronic hepatitis C virus (HCV) infection. Dipeptidylpeptidase 4 (DPPIV) cleaves active IP-10 into an inactive form, which inhibits recruitment of CXCR3+ T cells to the liver. In this study the link between IP-10 levels, DPPIV activity in serum and CXCR3+ T cells is analysed in cholestatic and non-cholestatic liver patients. Methods In serum DPPIV activity (by enzymatic assay), IP-10 (by ELISA) and bile acids (BA)

Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain

Tuesday, December 04, 2018 -- by Regina Juanbeltz, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Silvia Goñi-Esarte, Jesús Repáraz, José Manuel Zozaya, Ramón San Miguel, Carmen Ezpeleta, Jesús Castilla, EIPT-VHC Study Group Background The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress and difficulties in the elimination of HCV infection in Navarra, Spain. Methods Using electronic healthcare databases, we performed a population-based prospective cohort study to describe changes in the prevalence of diagnosed active HCV infection at the beginning of 2015 and the end of 2017, the rate of new diagnoses and the rate of post-treatment viral clearance (PTVC) during this

Oregon to expand Medicaid coverage to more hepatitis C patients

Monday, December 03, 2018 -- Oregon Health Authority Director Patrick Allen said he will approve a proposal to remove limits on coverage for hepatitis C treatment. The Oregon Drug Use Review/Pharmacy & Therapeutics Committee, which advises OHA on prescription drug coverage, on Thursday recommended a change in prior authorization criteria. The change will allow all Medicaid patients with chronic hepatitis C to receive treatment, without fibrosis-related restrictions. “I look forward to approving this recommendation to expand…

Treatment for HCV regardless of SVR lowers risk for CVD events

Wednesday, December 05, 2018 -- Treatment with either pegylated interferon with ribavirin or direct-acting antivirals for hepatitis C correlated with a significantly lower risk for cardiovascular disease, especially among patients who achieved sustained virologic response, according to a study published in Gastroenterology.“We found that untreated HCV infected persons had nearly twice the rate of incident CVD events compared with those who initiated treatment. This was observed for [coronary artery disease (CAD)] events ... as well as for stroke and peripheral vascular disease,” Adeel A. Butt, MD, from the

Higher complication rate in patients with hepatitis C after hip fracture surgery

Tuesday, December 04, 2018 -- Patients with noncirrhotic hepatitis C infection had a negative association with hip fracture surgery outcomes, according to data published in the Journal of Orthopaedic Trauma.Using the National Hospital Discharge Survey, researchers divided patients with hip fractures who were surgically treated into whether they had a diagnosis of hepatitis C (n = 5,377) or did not (n = 4,712,159). Investigators collected demographic variables and categorized adverse events into general medical complications, mechanical complications and surgical complications. They also analyzed data for length of stay

Perinatal HCV Spurs Earlier Cirrhosis

Monday, December 03, 2018 -- (MedPage Today) -- Researchers stress need for young people to have access to new treatments

Perinatal HCV Causes Earlier Cirrhosis (CME/CE)

Wednesday, December 05, 2018 -- (MedPage Today) -- Study demonstrates the need for children and young adults to receive early HCV treatment